Thought leader views on new osteoporosis and osteopenia treatments

5 April 2013

US and European primary care physicians (PCPs) agree that efficacy on hip fracture risk reduction is one of the attributes that most influences their decisions regarding prescribing in osteoporosis and osteopenia, according to new research from health care advisory firm Decision Resources.

Clinical data and the opinions of interviewed thought leaders indicate that Amgen (Nasdaq: AMGN) and UCB's (Euronext Brussels: UCB) AMG-785/CDP-7851 and Merck & Co’s (NYSE: MRK) odanacatib have advantages over patient share leader alendronate (Merck’s Fosamax, Teijin's Bonalon, generics) on this attribute.

The DecisionBase 2013 report - titled Emerging Therapies AMG-785/CDP-781 and Odanacatib Are Poised to Overtake Teriparatide's Status as the Clinical Gold Standard - also finds that, based on clinical data and the opinions of interviewed thought leaders, teriparatide (Eli Lilly's [NYSE: LLY] Forteo/Forsteo, Asahi Kasei's Teribone) is Decision Resources' current proprietary clinical gold-standard therapy for osteoporosis and osteopenia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK